TriSalus Life Sciences announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Q4 2024 revenue, driven solely by the TriNav Infusion System, was approximately $8.3 million, representing a 44% growth versus the fourth quarter of 2023.
For the full year 2024, revenue was approximately $29.4 million, marking a 59% growth versus the full year 2023. Operating Cash Flow in the fourth quarter of 2024 was approximately ($5.6) million, showing a notable improvement compared to the previous quarter's ($10.8) million.
As of December 31, 2024, cash and cash equivalents were approximately $8.5 million. The company expects to qualify for an additional $10 million tranche of its OrbiMed debt agreement in Q1 2025 and anticipates sufficient liquidity to fund operations through 2025, reaffirming its guidance for over 50% revenue growth, positive full year EBITDA, and positive cash flow in the second half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.